Endogenous fibrinolytic function and risks of future myocardial infarction and stroke: Observations from the physicians' health study

Fibrinolysis and Proteolysis

Volumn 11, Issue SUPPL. 1, 1997, Pages 55-59

  Ridker, P M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; ALCOHOL CONSUMPTION; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CORONARY RISK; FIBRINOLYSIS; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING; STROKE; THROMBOSIS;

EID: 0030669407     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80024-0     Document Type: Conference Paper

References (20)

1. Hamsten A, Walldius G, Szamosi A et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
2. Meade T W, Mellows S, Brozovic M et al. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-537.
3. Ridker P M, Vaughan D E, Stampfer M J, Manson J E, Hennekens C H. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-1168.
4. Ridker P M, Hennekens C H, Stampfer M J, Manson J E, Vaughan D E. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343: 940-943.
5. Thompson S G, Kienast J, Pyke S D M et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-641.
6. Ridker P M, Vaughan D E, Stampfer M J, Sacks F M, Hennekens C H. A cross-sectional study of endogenous tissue plasminogen activator, total cholesterol, HDL cholesterol, and apolipoproteins A-I, A-II, and B-100. Arteriosclerosis and Thrombosis 1993; 13: 1-6.
7. Jansson J H, Olofsson B O, Nilsson T K. Predictive value of tissue plasminogen activator mass concentration on long term mortality in patients with coronary artery disease: A seven year follow-up. Circulation 1993; 88: 2030-2034.
8. Meade T W, Ruddock V, Stirling Y, Charkrabarti R, Miller G J. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-1079.
9. Ridker P M, Hennekens C H, Cerskus A, Stampfer M J. Plasma concentration of cross linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994; 90: 2236-2240.
10. Ridker P M, Vaughan D E, Stampfer M J, Manson J E, Shen C, Newcomer L M, Goldhaber S Z, Hennekens C H. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation 1992; 85: 1822-1827.
11. Ridker P M, Hennekens C H, Lindpaintner K, Stampfer M J, Eisenberg P R, Miletich J P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-917.
12. Vague P, Juhan-Vague I, Aillaud M R et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986; 35: 250-253.
13. Nabulsi A A, Folsom A R, White A et al. for the Atherosclerosis Risk in Communities Study Investigators. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328: 1069-1075.
14. Ridker P M, Vaughan D E, Stampfer M J, Hennekens C H. Association of moderate alcohol consumption and plasma concentration of endogenous tissue plasminogen activator. JAMA 1994; 272: 929-933
15. Dawson S J, Wiman B, Hamsten A, Green F, Humphries S, Henney A M. The two allele sequences of a common polymorphism in the promotor of the plasminogen activator inhibitor (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-10745.
16. Eriksson P, Kallin B, van't Hooft F M, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92:1851-1855.
17. Ridker P M, Hennekens C H, Lindpaintner K, Stampfer M J, Miletich J P. Arterial and Venous Thrombosis is Not Associated with the 4G/5G Polymorphism in the Promotor of the Plasminogen Activator Inhibitor (PAI-1) Gene in a Large Cohort of US Men. Circulation 1997 (in press).
18. Ridker P M, Gaboury C L, Conlin P R, Seely E W, Williams G H, Vaughan D E. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: Evidence of a potential interaction between the renin angiotensin system and fibrinolytic function. Circulation 1993; 87: 1969-1973.
19. Ridker P M, Vaughan D E. Potential antithrombotic and fibrinolytic properties of the angiotensin converting enzyme inhibitors. J Thromb Thrombolysis 1995; 1: 251-257.
20. Wright R A, Flapan A D, Alberti K G, Ludlam C A, Fox K A. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Card 1994; 24: 67-73.